QUAD Investment Management

HoneyNaps is focused on developing a bio-signal monitoring device aimed at addressing sleep disorders. The company's platform is designed to collect and analyze various data points, including body temperature, heart rate, breathing, and movement during sleep. By providing this comprehensive data analysis, HoneyNaps enables medical professionals and researchers to identify and respond to any abnormal symptoms associated with sleep disorders, facilitating more effective treatment options.

NeoCannBio provides natural product processing facilities for generating new medications derived from natural goods and built a cannabinoid library of hemp, and medical cannabis.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Good Food For Good operates as a food & lifestyle brand company.

Avelos Therapeutics is a clinical-stage precision medicine company that specializes in the development of biomarker-driven anti-cancer therapies. The company focuses on creating targeted therapeutics that address critical areas such as cell cycle regulation, DNA damage response, and undruggable cancer targets. By leveraging these innovative approaches, Avelos aims to enhance the effectiveness of cancer treatment, allowing healthcare professionals to provide more tailored and efficient care to patients.

KaliVir Immunotherapeutics focuses on developing innovative oncolytic viral immunotherapy products aimed at treating various tumor types. The company utilizes a novel oncolytic vaccinia platform to enhance the systemic delivery of therapies through intravenous methods, ensuring targeted replication and effective viral spread within tumors. Their programs incorporate both in-house technologies and licensed advancements from the University of Pittsburgh, a leader in oncolytic virus and immunotherapy research. By leveraging proprietary genetic modifications, KaliVir aims to provide healthcare professionals with advanced treatment options that harness the body's immune response to combat cancer effectively.

Curiox Biosystems Pte. Ltd. is a bioinstrumentation company based in Singapore, specializing in the development and commercialization of innovative assay platforms. Founded in 2007 and spun out of the Agency for Science, Technology, and Research (A*STAR), Curiox focuses on enhancing life sciences, drug discovery, and diagnostics through the miniaturization and automation of bioassays. The company offers a range of products, including DropArray microplates for miniaturized cell and Luminex assays, as well as various washing stations designed for both automatic and manual loading. Their technology, including the Laminar Wash systems, improves the efficiency and reproducibility of cell processing and analysis. Curiox's product offerings also include plates, fluids, and service contracts, catering to applications such as bead-based immunoassays, suspension cell assays, high content assays, and induced pluripotent stem cells.

Pear Therapeutics, Inc. is a healthcare company specializing in the discovery, development, and delivery of software-based therapeutics aimed at treating behavioral health disorders, including addiction, schizophrenia, anxiety, depression, and chronic insomnia. Founded in 2013 and headquartered in Boston, with an additional office in San Francisco, Pear Therapeutics offers a range of digital therapies designed to enhance treatment outcomes. Notable products include reSET, a tool for substance abuse treatment used alongside traditional therapy; reSET-O, which addresses opioid use disorder; and Somryst, aimed at chronic insomnia. The company also provides PearConnect, a patient services center that connects users with advocates, clinicians, and insurance providers to facilitate support and resource access throughout treatment. By integrating digital interventions with pharmaceuticals, Pear Therapeutics aims to improve patient engagement, clinical outcomes, and cost-effectiveness in healthcare.

Bisu is a health technology company that offers a home health lab designed to enhance personal well-being through urine and saliva tests. Its devices monitor various health metrics, including dietary health, fat metabolism, and hydration levels, providing users with daily feedback on electrolytes, hydration, pH, ketones, and uric acid via a mobile application. This functionality enables individuals to track burned body fat, maintain metabolic health, achieve optimal ketosis, and improve physical endurance. Bisu has received recognition for its innovation, having been awarded by prestigious organizations such as Johnson & Johnson Innovation and MedTech Innovator, and it gained further acclaim at CES 2020 with the IHS Markit Innovation Award.

Akili Interactive is a digital medicine company focused on developing innovative cognitive treatments using technology. The company has a diverse pipeline of programs designed to address cognitive deficiencies and alleviate symptoms associated with various medical conditions. These include attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD), and several inflammatory diseases. By leveraging engaging digital platforms, Akili aims to improve patient outcomes in the fields of neurology and psychiatry through its unique therapeutic approaches.

Medipixel, Inc., founded in 2017 and based in Seoul, South Korea, specializes in developing artificial intelligence-based diagnostic software and semi-autonomous surgical tools for lung cancer and cardiac disease interventions. The company employs a team of experts in computer vision, deep learning, and reinforcement learning, collaborating with leading healthcare institutions to enhance diagnostic and surgical processes. Medipixel offers several innovative solutions, including an AI-based diagnosis tool that assists doctors in identifying lesions during coronary angiography, a guide and planning solution that visualizes hidden coronary artery segments to facilitate guidewire manipulation, and an automated navigation engine that optimizes robotic control for surgical procedures. By integrating advanced AI technologies, Medipixel aims to improve the quality of medical care and patient outcomes in the field of surgery.

Pear Therapeutics, Inc. is a healthcare company specializing in the discovery, development, and delivery of software-based therapeutics aimed at treating behavioral health disorders, including addiction, schizophrenia, anxiety, depression, and chronic insomnia. Founded in 2013 and headquartered in Boston, with an additional office in San Francisco, Pear Therapeutics offers a range of digital therapies designed to enhance treatment outcomes. Notable products include reSET, a tool for substance abuse treatment used alongside traditional therapy; reSET-O, which addresses opioid use disorder; and Somryst, aimed at chronic insomnia. The company also provides PearConnect, a patient services center that connects users with advocates, clinicians, and insurance providers to facilitate support and resource access throughout treatment. By integrating digital interventions with pharmaceuticals, Pear Therapeutics aims to improve patient engagement, clinical outcomes, and cost-effectiveness in healthcare.

4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing innovative gene therapy products to address unmet medical needs. The company utilizes targeted and evolved adeno-associated virus vectors to create a diverse portfolio of product candidates focused on ophthalmology, cardiology, and pulmonology. Among its key projects are 4D-125, currently in a Phase I/II clinical trial for X-linked retinitis pigmentosa; 4D-110, in a Phase I clinical trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is advancing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. Founded in 2013, the company is dedicated to transforming the treatment landscape in these therapeutic areas.

Korea Credit Data Co., Ltd. is a business management software provider based in Seoul, South Korea, founded in 2016. The company specializes in offering essential services to small and medium enterprises, including business management, customer analysis, point-of-sale (POS) and payment services, as well as a marketplace platform. Its flagship product, CashNote, allows users to manage card payment schedules, conduct customer analysis, and perform tax invoice inquiries. Korea Credit Data serves over two million businesses across the country and aims to address various challenges faced by business owners throughout their operational journey. The company has expanded its services to include payment solutions and credit bureau functions, having secured a credit bureau license after 17 years. Through strategic partnerships with leading industry players, Korea Credit Data has established a strong market presence and raised significant investment to further enhance its offerings.

Medipixel, Inc., founded in 2017 and based in Seoul, South Korea, specializes in developing artificial intelligence-based diagnostic software and semi-autonomous surgical tools for lung cancer and cardiac disease interventions. The company employs a team of experts in computer vision, deep learning, and reinforcement learning, collaborating with leading healthcare institutions to enhance diagnostic and surgical processes. Medipixel offers several innovative solutions, including an AI-based diagnosis tool that assists doctors in identifying lesions during coronary angiography, a guide and planning solution that visualizes hidden coronary artery segments to facilitate guidewire manipulation, and an automated navigation engine that optimizes robotic control for surgical procedures. By integrating advanced AI technologies, Medipixel aims to improve the quality of medical care and patient outcomes in the field of surgery.

Curiox Biosystems Pte. Ltd. is a bioinstrumentation company based in Singapore, specializing in the development and commercialization of innovative assay platforms. Founded in 2007 and spun out of the Agency for Science, Technology, and Research (A*STAR), Curiox focuses on enhancing life sciences, drug discovery, and diagnostics through the miniaturization and automation of bioassays. The company offers a range of products, including DropArray microplates for miniaturized cell and Luminex assays, as well as various washing stations designed for both automatic and manual loading. Their technology, including the Laminar Wash systems, improves the efficiency and reproducibility of cell processing and analysis. Curiox's product offerings also include plates, fluids, and service contracts, catering to applications such as bead-based immunoassays, suspension cell assays, high content assays, and induced pluripotent stem cells.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.

Korea Credit Data Co., Ltd. is a business management software provider based in Seoul, South Korea, founded in 2016. The company specializes in offering essential services to small and medium enterprises, including business management, customer analysis, point-of-sale (POS) and payment services, as well as a marketplace platform. Its flagship product, CashNote, allows users to manage card payment schedules, conduct customer analysis, and perform tax invoice inquiries. Korea Credit Data serves over two million businesses across the country and aims to address various challenges faced by business owners throughout their operational journey. The company has expanded its services to include payment solutions and credit bureau functions, having secured a credit bureau license after 17 years. Through strategic partnerships with leading industry players, Korea Credit Data has established a strong market presence and raised significant investment to further enhance its offerings.

ABL Bio Inc. is a South Korean biotech research company dedicated to developing therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company's pipeline includes ABL001, a bispecific antibody for cancer immunotherapy, and several antibody-drug conjugates (ADCs) such as ABL201-205. Additionally, ABL Bio is working on T cell engagers and dual immune cell targeting bispecific antibodies to enhance immuno-oncology treatments. Another notable product in development is ABL301, designed as a blood-brain barrier-penetrating bispecific antibody. The company emphasizes innovation and collaboration in its mission to improve lives through novel therapies.